Description
What is Ibrutinib and what it is used for:
Ibrutinib is a thalidomide analogue drug. Ibrutinib is recommended for the treatment of patients with:- Mantle cell lymphoma who have received at least one therapy earlier.
- Chronic lymphocytic leukemia/Small lymphocytic lymphoma.
- Small lymphocytic lymphoma(SML) or Chronic lymphocytic leukemia (CML) with 17p deletion.
- Waldenström’s macroglobulinemia (WM)
- Marginal zone lymphoma patients who need systemic therapy and have received at least one anti-CD20-based therapy earlier.
- Chronic graft-versus-host disease (cGVHD) after the failure of one or more lines of systemic therapy.
Source: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205552s026,210563s002lbl.pdf
Recommended Dosage
Ibrutinib should be taken orally at about the same time each day with a glass of water. Do not cut, crush or chew. Ibrutinib capsules must be gulped whole with water. One should avoid opened, broken, or chewed capsules.- In Mantle Cell Lymphoma and Marginal Zone Lymphoma patients: The dose of Ibrutinib recommended by healthcare professionals for Mantle Cell Lymphoma and Marginal Zone Lymphoma is 560 mg orally once daily until disease progression or unacceptable toxicity.
- In Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Waldenström’s Macroglobulinemia patients: The recommended dose of Ibrunat for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Waldenström’s Macroglobulinemia is 420 mg orally once daily until disease progression or unacceptable toxicity. The recommended dose of Ibrunat for CLL/SLL when used in combination with bendamustine and rituximab (administered every 28 days for up to 6 cycles) is 420 mg orally once daily until disease progression or unacceptable toxicity.
- In Chronic Graft versus Host Disease patients: The recommended dose of Ibrunat for Chronic Graft versus Host Disease is 420 mg orally once every day until cGVHD progression, recurrence of an underlying malignancy, or unacceptable toxicity. When a patient no longer needs the therapy for the treatment of cGVHD, Ibrunat should be discontinued, considering the medical assessment of the individual patient.
Ibrutinib side effects:
The most common adverse reactions include diarrhea, thrombocytopenia, neutropenia, fatigue, anemia, musculoskeletal pain, bruising, upper respiratory tract infection, rash, and nausea.